Moleculin Biotech (NASDAQ:MBRX) Research Coverage Started at

StockNews.com assumed coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a report released on Sunday morning. The brokerage issued a sell rating on the stock. Other analysts have also recently issued research reports about the company. Maxim Group cut their target price on Moleculin Biotech from $45.00 to $20.00 and set a […]

Related Keywords

Roth Mkm , Nasdaq , Moleculin Biotech Inc , Atticus Wealth Management , Exchange Commission , Maxim Group , Moleculin Biotech , Free Report , Wealth Management , Get Free Report , Moleculin Biotech Daily , Nasdaq Mbrx , Ambrx , Medical , Initiated Coverage , Stocknews Com ,